All In Biotech

Drug Trial Radar · NCT02305797

EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)

A Randomized Double-Blind, Placebo Controlled, Flexible Dose, Parallel Group Study of Extended-Release Lorazepam (EDG004) for the Treatment of Generalized Anxiety Disorder (GAD)

Last checked: Nov 19, 2026Latest source record: Sep 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 495 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

495

Actual

Start

Jan 2015

Primary completion

May 2016

Study completion May 2016

Sponsor

Lead sponsor
Edgemont Pharmaceuticals, LLCIndustry
Sponsor type
Industry
First posted
Dec 3, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of EDG004 compared to placebo for the treatment of adult patients with GAD, diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. (DSM-5) and confirmed by the Mini International Neuropsychiatric Interview (MINI 7.0). Efficacy will be measured by a statistically significant greater mean reduction from baseline compared to endpoint in anxiety symptoms as measured by the total score of the clinician-rated Hamilton Rating Scale for Anxiety (HAM-A) for the EDG004 treatment group compared to placebo.

Conditions

  • Generalized Anxiety Disorder (GAD)

Interventions

  • Extended-release lorazepamDrug

    Extended-release lorazepam capsules

  • PlaceboDrug

    Placebo capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Visit 7 (Day 42)Time frame: Day 42 (Visit 7)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Multiple Investigational Sites

    Multiple Locations, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.